HELM AG acquires 30% stake in Argentina's Amarin Technologies

16 December 2010

Hamburg, Germany-based HELM AG says that, at end September, it purchased a 30% shareholding in Amarin Technologies SA, a privately owned pharmaceutical development company in Buenos Aires, Argentina. Financial terms of the deal were not disclosed.

Amarin has more than 20 years of experience in the technology of transdermal delivery systems and owns several patents. The mid-size company has been cooperating with HELM successfully on the development of a pain release patch.

Both Sergio Lucero, chief executive of Amarin, and Dieter Schnabel, CEO of HELM, says they are convinced that HELM, with its marketing strength in more than 32 countries is a perfect fit for Amarin’s expertise in transdermal technology. “We are confident that this strategic step will be very beneficial to both companies,” they stated yesterday.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK